• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

United States Centers for Disease Control and Prevention issue updated guidance for tackling carbapenem-resistant enterobacteriaceae (Euro Surveill.,

Giuseppe

Emeritus
[Source: Eurosurveillance, full page: (LINK). Edited.]

Eurosurveillance, Volume 17, Issue 26, 28 June 2012

News

United States Centers for Disease Control and Prevention issue updated guidance for tackling carbapenem-resistant enterobacteriaceae


A Kallen ()<SUP>1</SUP>, A Guh<SUP>1</SUP>
  1. Centers for Disease Control and Prevention, Atlanta, Georgia, United States
<HR>
Citation style for this article: Kallen A, Guh A. United States Centers for Disease Control and Prevention issue updated guidance for tackling carbapenem-resistant enterobacteriaceae. Euro Surveill. 2012;17(26):pii=20207. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20207
Date of submission: 27 June 2012
<HR>On 21 June, the United States (US) Centers for Disease Prevention and Control (CDC) released a report [1] and updated recommendations [2] that detail how states and healthcare facilities should deal with carbapenem-resistant Enterobacteriaceae (CRE), deadly germs that cause healthcare-associated infections. The report documents the first case of person-to-person transmission in the US of CRE with New Delhi metallo-beta-lactamase (NDM), first reported in 2007. CRE with NDM are of particular concern because these enzymes allow drug resistance to be transferred easily from one bacterium to another.

CRE are resistant to almost all drugs and can contribute to death in 40% of patients who become infected [3]. In response to this emerging threat, the CDC have urged healthcare facilities and US state health departments to take action and follow several key steps to protect patients.

Healthcare providers should:
  • place patients currently or previously colonised or infected with CRE on contact precautions;
  • wear a gown and gloves when caring for patients with CRE;
  • perform hand hygiene - use alcohol-based hand rub or wash hands with soap and water before and after contact with patients or their environment;
  • prescribe and use antibiotics wisely; and
  • discontinue devices like urinary catheters as soon as no longer necessary.
Klebsiella pneumoniae carbapenemase (KPC) is the most common carbapenemase in the US and has spread throughout many regions [4]. Although the prevalence of CRE likely varies from region to region, a review of data from CDC?s National Healthcare Safety Network found that in 2009-2010 in the USt, about 13% of Klebsiella species reported from central line-associated bloodstream infections (CLABSIs) and catheter-associated urinary tract infections (CAUTIs) were carbapenem-nonsusceptible. About 2% of Escherichia coli reported from CLABSIs and CAUTIs were carbapenem-nonsusceptible.

Genes coding for KPC can be transmitted between bacteria via mobile genetic elements, potentially facilitating transmission of these organisms. Organisms producing metallo-beta-lactamase (NDM, VIM, and IMP) have also been identified in the US but appear to be less common than KPC-producing organisms.

In healthcare settings, CRE are usually transmitted from person to person, often via the hands of healthcare personnel or via contaminated medical equipment. To control CRE, healthcare providers should ensure the use of appropriate infection control procedures, including personal protective equipment during and good hand hygiene following exposure to the patient?s immediate environment, especially when draining urine from a catheter bag or changing wound dressings.

The CDC CRE website [5] at has information and resources for US patients, clinicians, healthcare facilities, and state health departments.

<HR>
References
  1. Centers for Disease Control and Prevention (CDC). Carbapenem-Resistant Enterobacteriaceae Containing New Delhi Metallo-Beta-Lactamase in Two Patients ? Rhode Island, March 2012. MMWR Morb Mortal Wkly Rep. 2012; 61:446-448.
  2. Centers for Disease Control and Prevention (CDC). Guidance for Control of Carbapenem-resistant Enterobacteriaceae (CRE). [Accessed 26 Jun 2012]. Available from: http://www.cdc.gov/hai/organisms/cre/cre-toolkit/index.html.
  3. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008;29:1099-106.
  4. Centers for Disease Control and Prevention CDC). Tracking CRE. [Accessed 26 Jun 2012]. Available from: http://www.cdc.gov/hai/organisms/cre/TrackingCRE.html
  5. Centers for Disease Control and Prevention CDC). Carbapenem-resistant Enterobacteriaceae (CRE). [Accessed 26 Jun 2012]. Available from: http://www.cdc.gov/HAI/organisms/cre/index.html
-
------
 
Back
Top Bottom